Aurinia Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Aurinia Pharmaceuticals Inc. (AUPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 1.30% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-02-15
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.30%, a 18.18% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 1.10%, a 266.67% increase from fiscal 2021.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 0.30%, a 25.00% decline from fiscal 2020.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2023-12-31 | 1.30% 10-K · filed 2024-02-15 |
| 2022-12-31 | 1.10% 10-K · filed 2024-02-15 |
| 2021-12-31 | 0.30% 10-K · filed 2024-02-15 |
| 2020-12-31 | 0.40% 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |